{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=9",
    "query": {
      "intervention": "A PROTEIN level",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1383,
    "total_pages": 139,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A+PROTEIN+level&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T04:45:25.619Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02543229",
      "title": "Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Diseases",
        "Macular Degeneration",
        "Retinal Diseases",
        "Retinal Degeneration",
        "Neovascularization, Pathologic"
      ],
      "interventions": [
        {
          "name": "OPT-302",
          "type": "DRUG"
        },
        {
          "name": "Lucentis™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opthea Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2015-07",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543229"
    },
    {
      "nct_id": "NCT06419777",
      "title": "Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gestational Diabetes",
        "Pregnancy Related"
      ],
      "interventions": [
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 430,
      "start_date": "2024-09-01",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 2,
      "location_summary": "Rochester, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06419777"
    },
    {
      "nct_id": "NCT03587831",
      "title": "Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Vertical Sleeve Gastrectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Lifestyle Modification Counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-07-01",
      "completion_date": "2026-06-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Baton Rouge, Louisiana • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03587831"
    },
    {
      "nct_id": "NCT03882437",
      "title": "Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Danon Disease"
      ],
      "interventions": [
        {
          "name": "RP-A501",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rocket Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "8 Years and older · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2019-04-17",
      "completion_date": "2025-07-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Aurora, Colorado • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03882437"
    },
    {
      "nct_id": "NCT04855253",
      "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "DLBCL",
        "Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "DLBCL Arising From Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "E7777",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tisagenlecleucel",
          "type": "DRUG"
        },
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "DRUG"
        },
        {
          "name": "Lisocabtagene Maraleucel Intravenous Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04855253"
    },
    {
      "nct_id": "NCT06789172",
      "title": "A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumours",
        "Sarcoma",
        "HNSCC",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Colorectal Cancer (CRC)",
        "Myxofibrosarcoma (MFS)",
        "Solitary Fibrous Tumors",
        "Dedifferentiated Liposarcoma",
        "Undifferentiated Pleomorphic Sarcoma (UPS)",
        "Leiomyosarcoma",
        "Leiomyosarcoma (LMS)",
        "Gastric Cancer (GC)",
        "Gastric Cancer Adenocarcinoma Metastatic",
        "Gastric / Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "OKN4395",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fasting",
          "type": "OTHER"
        },
        {
          "name": "Fed",
          "type": "OTHER"
        },
        {
          "name": "H2 Receptor Antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Epkin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2025-01-23",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Santa Monica, California • Houston, Texas",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789172"
    },
    {
      "nct_id": "NCT04674306",
      "title": "Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer",
        "TNBC - Triple-Negative Breast Cancer",
        "Residual Disease"
      ],
      "interventions": [
        {
          "name": "α-lactalbumin vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Zymosan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "George T. Budd",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2021-10-01",
      "completion_date": "2025-12-29",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04674306"
    },
    {
      "nct_id": "NCT00069238",
      "title": "Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, T-Cell",
        "Lymphoma, Extranodal NK-T-Cell"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab (Campath)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EPOCH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2003-09-19",
      "completion_date": "2021-03-17",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00069238"
    },
    {
      "nct_id": "NCT03666000",
      "title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "B-cell Acute Lymphoblastic Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Azer-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Imugene Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2019-03-11",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 10,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03666000"
    },
    {
      "nct_id": "NCT00565864",
      "title": "Neurocognitive and Metabolic Effects of Mild Hypothyroidism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypothyroidism"
      ],
      "interventions": [
        {
          "name": "L-thyroxine (L-T4)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 173,
      "start_date": "2008-08",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-10-14T04:45:25.619Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00565864"
    }
  ]
}